B-J Kim1, K-O Shin2, H Kim1, S H Ahn1, S H Lee1, C-H Seo2, S-E Byun3, J S Chang4, J-M Koh5, Y-M Lee6. 1. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138-736, Korea. 2. College of Pharmacy and MRC, Chungbuk National University, Cheongju, 361-763, Korea. 3. Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University, Seongnam, 463-712, Korea. 4. Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138-736, Korea. 5. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138-736, Korea. jmkoh@amc.seoul.kr. 6. College of Pharmacy and MRC, Chungbuk National University, Cheongju, 361-763, Korea. ymleefn@daum.net.
Abstract
BACKGROUND: Although recent studies provide clinical evidence that sphingosine-1-phosphate (S1P) may primarily affect bone resorption in humans, rather than bone formation or the osteoclast-osteoblast coupling phenomenon, those studies could not determine which bone resorption mechanism is more important, i.e., chemorepulsion of osteoclast precursors via the blood to bone marrow S1P gradient or receptor activator of NF-κB ligand (RANKL) elevation in osteoblasts via local S1P. AIM: To investigate how S1P mainly contributes to increased bone resorption in humans, we performed this case-control study at a clinical unit in Korea. METHODS: Blood and bone marrow samples were contemporaneously collected from 70 patients who underwent hip surgery due to either osteoporotic hip fracture (HF) (n = 10) or other causes such as osteoarthritis (n = 60). RESULTS: After adjusting for sex, age, BMI, smoking, alcohol, previous fracture, diabetes, and stroke, subjects with osteoporotic HF demonstrated a 3.2-fold higher plasma/bone marrow S1P ratio than those without HF, whereas plasma and bone marrow S1P levels were not significantly different between these groups. Consistently, the risk of osteoporotic HF increased 1.38-fold per increment in the plasma/bone marrow S1P ratio in a multivariate adjustment model. However, the odds ratios for prevalent HF according to the increment in the plasma and bone marrow S1P level were not statistically significant. CONCLUSION: Our current results using simultaneously collected blood and bone marrow samples suggest that the detrimental effects of S1P on bone metabolism in humans may depend on the S1P gradient between the peripheral blood and bone marrow cavity.
BACKGROUND: Although recent studies provide clinical evidence that sphingosine-1-phosphate (S1P) may primarily affect bone resorption in humans, rather than bone formation or the osteoclast-osteoblast coupling phenomenon, those studies could not determine which bone resorption mechanism is more important, i.e., chemorepulsion of osteoclast precursors via the blood to bone marrow S1P gradient or receptor activator of NF-κB ligand (RANKL) elevation in osteoblasts via local S1P. AIM: To investigate how S1P mainly contributes to increased bone resorption in humans, we performed this case-control study at a clinical unit in Korea. METHODS: Blood and bone marrow samples were contemporaneously collected from 70 patients who underwent hip surgery due to either osteoporotic hip fracture (HF) (n = 10) or other causes such as osteoarthritis (n = 60). RESULTS: After adjusting for sex, age, BMI, smoking, alcohol, previous fracture, diabetes, and stroke, subjects with osteoporotic HF demonstrated a 3.2-fold higher plasma/bone marrow S1P ratio than those without HF, whereas plasma and bone marrow S1P levels were not significantly different between these groups. Consistently, the risk of osteoporotic HF increased 1.38-fold per increment in the plasma/bone marrow S1P ratio in a multivariate adjustment model. However, the odds ratios for prevalent HF according to the increment in the plasma and bone marrow S1P level were not statistically significant. CONCLUSION: Our current results using simultaneously collected blood and bone marrow samples suggest that the detrimental effects of S1P on bone metabolism in humans may depend on the S1P gradient between the peripheral blood and bone marrow cavity.
Entities:
Keywords:
Bone marrow S1P; Gradient; Hip fracture; Osteoporosis; Plasma S1P
Authors: Stacey A Wainwright; Lynn M Marshall; Kristine E Ensrud; Jane A Cauley; Dennis M Black; Teresa A Hillier; Marc C Hochberg; Molly T Vogt; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2005-02-22 Impact factor: 5.958
Authors: Yutong Zhao; Satish K Kalari; Peter V Usatyuk; Irina Gorshkova; Donghong He; Tonya Watkins; David N Brindley; Chaode Sun; Robert Bittman; Joe G N Garcia; Evgeni V Berdyshev; Viswanathan Natarajan Journal: J Biol Chem Date: 2007-03-22 Impact factor: 5.157
Authors: Ulrike Peest; Sven-Christian Sensken; Paul Andréani; Petra Hänel; Paul P Van Veldhoven; Markus H Gräler Journal: J Cell Biochem Date: 2008-06-01 Impact factor: 4.429
Authors: Justus M Grewe; Paul-Richard Knapstein; Antonia Donat; Shan Jiang; Daniel J Smit; Weixin Xie; Johannes Keller Journal: Bone Res Date: 2022-04-08 Impact factor: 13.567
Authors: Mohammed-Salleh M Ardawi; Abdulrahim A Rouzi; Nawal S Al-Senani; Mohammed H Qari; Ayman Z Elsamanoudy; Shaker A Mousa Journal: J Bone Metab Date: 2018-05-31